Circulating Tumor Dna

BARCELONA —STK11 and KEAP1 mutations appeared associated with poorer outcomes among patients with metastatic non-small cell lung cancer regardless of treatment with chemotherapy or immunotherapy, according to results of an exploratory analysis of the phase 3 MYSTIC trial presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Healio spoke with Roberto A. Leon-Ferre, MD, about exciting research in breast cancer.